Inclusion Criteria:

- Subject must be male or female ≥ 18 years at the time of signing Informed Consent.

- Subject was previously diagnosed with Multiple Myeloma and has failed at least one
prior treatment regimen for the disease.

- Subject must have measurable disease.

- Subjects must have relapsed or relapsed/refractory disease as defined in Appendix 4.

- Subject must have a life expectancy of greater than 6 months.

- Subject has an ECOG Performance status of 0 to 2 (Appendix 2).

- Subject has no prior history of HIV-1, HIV-2, Hepatitis B or C infection.

- Subject has a normal 12 lead ECG or an ECG with an abnormality considered to be
clinically insignificant.

- Subject has the ability to communicate with the investigative site staff in a manner
sufficient to carry out all protocol procedures as described.

- Subject must be able to adhere to the study visit schedule and other protocol
requirements.

- Subject must understand and voluntarily sign an informed consent document.

- All subjects of reproductive potential must agree prior to study entry to use
adequate contraception (hormonal or double barrier method of birth control;
abstinence) for the duration of the study dosing and at least 12 weeks after
completion of study drug.

- Adequate end organ function, defined as the following:

- Total bilirubin < 2 x ULN, unless attributable to Gilbert's disease

- ALT (SGPT) and AST (SGOT) < 2.5 x ULN

- Creatinine < 2.0 x ULN

- ANC > 0.5 x 10^9/L

- Platelets > 20,000 cells/mm3

Exclusion Criteria:

- Intolerance to resveratrol, SRT501 or bortezomib or significant allergy to either
compound, boron or mannitol or significant prior toxicity with either agent that
would preclude the safe use of that agent. Prior therapy with either compound is
permitted.

- Subjects with other active malignancy, with the exception of basal cell or squamous
cell carcinoma of the skin.

- An uncontrolled intercurrent illness including, but not limited to, recent (≤ 6
months), ongoing or active infection, symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, acute diffuse infiltrative pulmonary or
pericardial disease, or psychiatric illness/social situations that would limit
compliance with study requirements.

- Subject with a history of or current gastro-intestinal diseases influencing drug
absorption, with the exception of an appendectomy.

- Women who are breast-feeding, pregnant, expect to become pregnant during the course
of the study, or are sexually active in a heterosexual relationship and are not using
a medically acceptable double barrier method birth control. Confirmation that the
subject is not pregnant must be established by a negative serum beta-hCG pregnancy
test result obtained during the Screening period. Pregnancy testing is not required
for post-menopausal or surgically sterilized women. Women relying solely on oral
contraceptives for birth control are excluded.

- Subjects who have had chemotherapy or radiotherapy within 4 weeks prior to signing
Informed Consent or those who have not recovered from adverse events due to agents
administered more than 4 weeks earlier.

- Subjects who are on any concurrent medications that may exhibit anti-neoplastic
therapy, with the exception of < 10 mg of prednisone or equivalent as indicated for
other medical conditions, or up to 100 mg of hydrocortisone as premedication for
administration of certain medications or blood products.

- Subjects currently taking any investigational therapies and/or dietary supplements
containing resveratrol.

- Subjects with peripheral neuropathy of Grade 2 or greater.

- Subjects with uncontrolled bleeding.

- Subjects with evidence of mucosal or internal bleeding and/or platelet refractory
(i.e., unable to maintain a platelet count ≥ 20,000 cells/mm3).

- Subjects with a hemoglobin < 8.0 g/dL. Transfusions and/or EPO treatment are
permitted in subjects who are potentially excluded by this criteria.

- Any condition, including laboratory abnormalities, that in the opinion of the
Investigator, would preclude treatment.